Urology Times

The ModernMedicine Network is a comprehensive platform that unites news, resources, tools, and educational programs from reliable and respected sources. It is curated by a team of experts, including advisors, consultants, influential voices, and content partners. ModernMedicine serves as a central news source for professionals in the healthcare industry.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#364890

United States

#154362

Health/Medicine

#1229

Traffic sources

Monthly visitors

Articles

Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 20, 2025Author(s):,Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete response rates, favorable safety profile, and potential to offer an effective, bladder-sparing alternative without the toxicity of systemic immunotherapy.
Topline Data From the BOND-003 Trial in NMIBC

1 week ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 20, 2025Author(s):,Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting promising response rates but significant toxicity concerns that currently limit widespread adoption to select high-risk patients, pending further trial data and safety protocol development.
Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection

1 week ago | urologytimes.com | Aaron Berger

Abiraterone Formulation Options and Patient AdherenceThis segment provides detailed information about the 3 main abiraterone acetate formulations available for treating metastatic castration-resistant prostate cancer. The traditional formulation requires 1000 mg daily (four 250-mg tablets) taken on an empty stomach with strict fasting requirements—no food 2 hours before and 1 hour after administration—combined with prednisone 5 mg twice daily.
A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

1 week ago | urologytimes.com | Aaron Berger

mCRPC Case PresentationThis segment presents a comprehensive case study of a man aged 74 years diagnosed with mCRPC. The patient’s journey began 4 years ago with high-risk localized prostate cancer, progressing through radical prostatectomy, biochemical recurrence, salvage radiation therapy, and eventually developing bone metastases.
What’s Next for NMIBC: The Immunotherapy and Gene Therapy Pipeline

2 weeks ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 13, 2025Author(s):,Panelists discuss current FDA-approved treatments for BCG-unresponsive carcinoma in situ, noting varying response rates among pembrolizumab, nadofaragene, and BCG combined with IL-15 superagonist, while highlighting promising investigational combination immunotherapies like oncolytic viruses and checkpoint inhibitors that may improve outcomes in this challenging patient population.
Weighing the Risks and Benefits of Bladder-Sparing Agents vs Cystectomy

2 weeks ago | urologytimes.com | Mark Tyson |Trinity J. Bivalacqua |Shreyas Joshi |Bogdana Schmidt

OpinionVideoJune 13, 2025Author(s):,Panelists discuss emerging data comparing bladder-sparing therapies to radical cystectomy in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting the nuanced trade-offs in oncologic outcomes and quality of life, and emphasizing the need for shared decision-making as prospective studies like CISTO refine patient selection for personalized treatment strategies.
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how recent advancements in NMIBC treatment, including the approval of nadofaragene firadenovec, pembrolizumab, and intravesical therapies like TAR-200, have reshaped care for BCG-unresponsive patients, with promising developments and ongoing trials at AUA 2025 paving the way for more personalized and effective treatment strategies in the future.
Navigating Access Barriers: Resources to Support New Treatment Access

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access barriers, ensuring that NMIBC patients receive timely access to novel treatments like nadofaragene firadenovec and pembrolizumab.
Overcoming Challenges in Accessing New Therapies for NMIBC

2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

OpinionVideoJune 12, 2025Author(s):,Panelists discuss how overcoming challenges such as cost, insurance coverage, regulatory hurdles, patient selection, and the need for education is crucial for improving access to novel therapies like nadofaragene firadenovec and pembrolizumab, ultimately enhancing outcomes for NMIBC patients.
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

2 weeks ago | urologytimes.com | Hannah Clarke

Second-line cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) demonstrated efficacy and manageable safety in patients with advanced renal cell carcinoma (RCC) regardless of the prior immunotherapy-based combination used in the first-line setting, according to data from a subgroup analysis of the phase 3 CONTACT-03 trial (NCT04338269).1The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.